Gefitinib for asymptomatic brain metastasis from advanced non‐small cell lung cancer: Report of a favourable outcome. Issue 4 (2nd February 2016) - Liu, Wen‐Yang
Abstract: Brain metastasis (BM) is common in patients with non‐small cell lung cancer (NSCLC). Although epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have now been included as standard treatment options for NSCLC harboring EGFR‐activating mutations, only a few prospective reports demonstrate the efficacy of these agents in a BM setting. We report a case of a patient with advanced NSCLC, in which oral gefitinib documented a significant antitumor effect on parallel progression of extracranial lesion and BM occurred during chemotherapy.